To the Editor
Inflammatory breast cancer (IBC) is a rare form of breast malignancy with unknown etiology, only accounting for 1% to 5% of all breast cancers. 1, 2 Compared with noninflammatory locally advanced breast cancer, IBC has a far higher incidence of locoregional recurrence and distant soft tissue and bone metastatic disease, resulting in worse prognosis and poorer survival. [3] [4] [5] [6] Current multimodality therapy regimens combining chemotherapy, mastectomy, and radiation have greatly improved patient survival. 1, 4, 7, 8 Recently developed novel targeted therapies also greatly benefit the management of IBC. 8 Because IBC commonly presents as diffuse disease in a large region of the breast, conventional imaging (mammogram and ultrasound) and clinical examination are inadequate in evaluating the primary breast lesion or the extent of disease. 9, 10 Breast imaging, especially magnetic resonance imaging (MRI), has been identified as one of the most important research areas. MRI is a potentially useful imaging modality for monitoring response of IBC during treatment, and it warrants further investigation.
Breast cancer patients achieving pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) were found to have longer disease-free survival and overall survival. [11] [12] [13] [14] The current NAC protocol for IBC is anthracycline-based regimen, 15, 16 with a reported pCR rate of <15%. 6, 17 The pCR rate of IBC after anthracycline and taxane treatment is reported to be between 12% and 33%. 18 The objective of this study was to investigate the role of breast MRI in the evaluation of NAC treatment in IBC patients by correlating the final MRI findings with the histopathological results after surgery. Considering the trend of breast-conservation surgery, an accurate post-NAC disease staging by MRI may facilitate surgical planning.
In a retrospective review of breast cancer patients in a single institution and enrolled onto a breast MRI study from the year 2003 to the year 2007, a total of 24 patients (age range, 29-77 years; mean age, 47 years) with IBC (stage IIIB-IV) were identified. The tumor size ranged from 2.5-16 cm (6.6 ± 3.2 cm). All of them had complete MRI follow-up studies and had undergone post-NAC surgery with available pathological results. Of the 24 patients, 19 had invasive ductal cancer, 3 had metaplastic cancer, and 2 had mixed ductal/lobular cancer. This study was approved by our institutional review board and complied with Health Insurance Portability and Accountability Act guidelines. All patients gave written informed consent for receiving the NAC treatment protocol and participating in the MRI study.
All IBC received the same treatment protocol. Biweekly dose-dense doxorubicin and cyclophosphamide (AC) was given as the first-line regimen. After the first two cycles of treatment, the patient's response was evaluated by the oncologist using all information available, including clinical examination, sonography, mammography, or MRI. If the patient responded well, she continued to receive two additional cycles of AC; otherwise, she was switched to a taxane-based regimen. After two cycles of AC, 6 patients showed marked reduction of tumor size (>30%), and 16 patients showed tumor reduction of <30%. Ten of these 16 patients were switched to a taxane-based regimen after two cycles of AC as a result of unremarkable treatment effect and very limited tumor size reduction. The second-line taxane-based regimen consisted of paclitaxel or nanoparticle albumin-bound (Nab)-paclitaxel combined with carboplatin. Fifteen of 24 IBC patients were HER-2 positive, and they also received trastuzumab with taxane. Nine HER-2-negative patients also received bevacizumab. The basic clinical, imaging, and pathological information of these 24 patients is listed in Table 1 .
In our NAC protocol, all patients had at least four breast MRI studies: a baseline breast MRI examination before NAC, at least two follow-up examinations during the course of therapy, and a final examination after completing the therapy protocol. The first follow-up MRI during the therapy was performed after two cycles of AC to determine early response and was taken as an early predictor for final NAC response. The second follow-up was performed after four cycles of AC or after two cycles of AC plus two cycles of taxane-based therapy to determine whether the patient responded well during the mid course of therapy. The final MRI after completion of all NAC was performed for correlation with pathology to assess the accuracy of MRI in defining residual tumor size and diagnosing pCR. Because the purpose of this study was to explore the feasibility of MRI for diagnosing residual tumor and pCR, only the final MRI was used for correlation.
The MRI was performed on a 1.5 T magnetic resonance scanner (Philips Medical Systems, Cleveland, OH). The contrast-enhanced dynamic imaging was performed by a three-dimensional SPGR (spoiled gradient echo) pulse sequence with 16 frames, 4 precontrast and 12 postcontrast. The detailed procedures for evaluating the response of lesions in MRI to chemotherapy have been described be-fore. 19 One radiologist (J.H.C.) with 3 years' experience in reading breast MRI performed the tumor size measurement. The radiologist was blinded to the pathology results. If the one-dimensional size reduction after completing NAC was<30% compared with their pretreatment size, the case was classified as nonresponding. When residual tumor was present with >30% size reduction, the case was classified as a partial response. Cases in which no enhanced tissues were visible, or with minimal enhancement magnitude equivalent to or lower than the normal breast tissue, were classified as complete clinical response. A breast MRI scientist (M.Y.S.) with 7 years' experience in reading breast MRIs also participated in interpreting final breast MRIs separately after completing NAC to determine whether clinically complete response had been achieved. Final consensus of both readers was used as the results in this study.
After completion of NAC, a definitive surgery was performed. The type of surgery was decided on the basis of the surgeon's recommendation and the patient's personal choice. Seventeen patients received mastectomy, and the other seven patients received lumpectomy. The detailed pathological examination procedures have been described previously. 19 The residual disease was recorded into one of three categories: (1) no residual cancer cells; (2) no residual invasive cancer, but with ductal carcinoma-in-situ present; and (3) residual invasive cancer. In this study, the pCR was defined as no invasive cancer. This definition was used at M. D. Anderson, 20 as was the consensus used at the Preoperative Therapy in Invasive Breast Cancer conference organized by the National Cancer Institute in March 2007. 21 In cases with evidence of residual invasive cancer, the pathological size was determined as the longest dimension-either the longest dimension on one hematoxylin and eosin-stained slide or from the number of blocks (each 5 mm) where the malignant invasive tumor was detected, whichever was greater. Pearson's correlation was used for comparing MRI determined residual tumor size and pathological size. P < .05 was considered statistically significant. Fisher's exact test was used to determine the significant difference of MRI for diagnosing pCR between HER-2-positive and HER-2-negative breast cancers.
Fifty percent (12 of 24) IBC patients experienced pCR. The MRI-evaluated complete clinical response was diagnosed in 67% (16 of 24) of IBC. Partial response was found in 29% (7 of 24), and the disease of one IBC patient was diagnosed as nonresponsive, showing <30% one-dimensional size reduction. The true-negative rate was 46%. The true-positive rate was 29% (7 of 24), and the false-negative rate was 21% (5 of 24). Overall, the sensitivity of MRI was 58% (7 of 12), and the specificity was 92% (11 of 12). The accuracy of MRI-diagnosed complete clinical response in predicting pCR was 69% (11 of 16) (Fig. 1) . Thirteen IBC with residual cancer either by MRI or pathological examination were included for the size correlation. The Pearson's correlation coefficient was r = .61. Nine of 13 patients had a discrepancy of >10 mm (up to 48 mm) (Fig. 2) . Among the three patients with the highest discrepancy (41, 47, and 48 mm), two presented non-mass-type diffuse enhancements, and one presented multiple mass lesions. The diagnostic performance of MRI for pCR in these 24 patients and further comparison between HER-2-positive and -negative patients are listed in Table 2 . No statistically significant difference was noted between the two groups.
Several studies have shown that pCR was the strongest prognostic factor for locally advanced breast cancer [11] [12] [13] [14] as well as for IBC. 22, 23 By means of our chemotherapy protocol, IBC achieved a pCR rate of 50%. Compared with other studies, our chemotherapy protocol seemed more effective for IBC to achieve the pCR. In a recent large series study, pCR was only achieved in 13.9% of IBC patients. 6 In another study, of 120 IBC patients who were randomized to receive high-dose fluorouracil, epirubicin, and cyclophosphamide, the pCR rate was only achieved in 14.7% patients. 17 When combining weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor followed by weekly paclitaxel as neoadjuvant therapy, the pCR rate of IBC was 33%. 18 Research on the accuracy of MRI in predicting pCR has been sporadically reported, [24] [25] [26] [27] without focusing on specific cancer types. In a recent study by Chen et al., 19 MRI was shown to be superior in correctly predicting pCR for HER-2-positive (18 of 19, 95%) rather than HER-2-negative (8 of 16, 50%) breast cancer, and the study concluded that the interpretation of residual disease on MRI may need to be more conservative for HER-2-negative patients. In this study, the accuracy of complete clinical response to predict pCR was 69% (11 of 16) in IBC. The false-negative rate was high (5 of 24, 21%), suggesting interpretation of the complete response in IBC by MRI should be more conservative. This is especially true for non-mass-type lesions, which accounted for four of these five false-negative cases. Regarding prediction of residual pathological tumor size by MRI, in 9 of 13 IBC patients, MRI under-or overestimated the tumor size by>1 cm. In three extreme cases with a size discrepancy of >4 cm, the pathological findings showed multiple islands of small residual invasive cancers distributed in a large area. This was also the major reason leading to false-negative finding in our previous study. 19 The results suggest that MRI findings may need to be interpreted cautiously when planning for conservation surgery, regardless of the lesion type. a The diagnostic accuracy of MRI for pathologic complete response was defined as the ratio between (true negative)/(true negative + false negative), which was not different between HER-2-positive and HER-2-negative patients. Sensitivity, defined as the ratio between (true positive)/(true positive + false negative), and specificity, defined as the ratio between (true negative)/(true negative + false positive), also did not show statistically significant differences between both groups of HER-2 patients.
Although breast-conserving surgery is traditionally considered contraindicated in IBC, 28 our current chemotherapy protocol has resulted in seven IBC patients who elected to receive lumpectomy after NAC. Further follow-up studies are needed to determine whether a great NAC response in IBC, along with the lesion types and initial presentations, may be used to select some IBC patients as good candidates for breast-conservation surgery.
Several limitations of our study exist. Although the subjects were collected over a period of 4 years, they came from a single institution, and the study number was small, making it difficult to draw clear conclusions about our results. The diagnosis of IBC was made on the basis of clinical presentations rather than pathological findings. However, a study of 71 diffuse IBC patients has shown that dermal lymphatic emboli were only noted in 45% of patients. 29 Therefore, pathological evaluation of skin specimen for diagnosis of IBC with skin involvement might not be necessary, and it was not performed in our study. The spatial resolution of the MRI images used in this study was suboptimal, which might affect the ability to detect small tumor foci. Our current protocol, with a 3 T magnetic resonance system, has improved spatial resolution as well as fat suppression. Postcontrast-enhanced images can now be directly evaluated without subtraction and are thus less prone to motion problems.
In our NAC protocol, although all patients had at least four breast MRI studies, they served different purposes. The first follow-up MRI was for evaluation of early tumor response and for early prediction of final treatment response. For this purpose, the imaging analysis demands morphological, kinetic, metabolic, and tumoral textual information aided by computed diagnosis. This is definitely beyond the scope of this study. Therefore, the detailed results and analytic techniques were not addressed in this paper. Because the purpose of this study was to explore the feasibility of MRI for diagnosing residual tumor and pCR, only the final MRI was used for correlation. Although the small number of subjects in our study means that a definite conclusion cannot be drawn, our results indicate that overall, MRI is still an appropriate imaging modality in the evaluation of IBC tumor response after NAC. Breast MRI provides clear imaging information for the change of tumor size during therapy, which is needed to demonstrate response versus nonresponse, and it allows oncologists to decide whether to continue the therapy or switch to another chemoregimen. However, MRI showed high false-negative diagnosis of pCR for non-mass-type tumor morphology, indicating that the use of MRI for diagnosing pCR in nonmass-type IBC should be more conservative. MRI also did not provide good accuracy in determining the final residual tumor size of IBC after NAC, causing obvious discrepancy of tumor size measurement between MRI and final pathology. This problem might be due to the intrinsic limitations of MRI in detecting small, scattered tumors and faintly enhanced residual tumor. The limitation should be considered when planning for breast-conservation surgery after NAC. A more aggressive surgical procedure might be needed for IBC. 
